Long-acting antiretroviral therapy suppresses HIV among people with unstable housing, mental illnesses, substance use
Long-acting antiretroviral therapy suppresses HIV among people with unstable housing, mental illnesses, substance use
NIH-supported study demonstrates injectable ART may improve outcomes in underserved patients.
A long-acting antiretroviral treatment (LA-ART) given every four to eight weeks, and delivered with comprehensive support services, suppressed HIV in people who were previously not virologically suppressed. This is according to an ongoing demonstration study of 133 people with HIV in San Francisco, funded by the National Institutes of Health. The study focused on reaching people who have historically had decreased access to antiretroviral therapy (ART), including people experiencing housing insecurity, mental illnesses, and substance use disorders. The study findings indicate that long-acting injectable ART can benefit people who face many treatment barriers and are historically underserved. (National Institute on Drug Abuse, USA, 21.02.2023)
https://nida.nih.gov/news-events/news-releases/2023/02/long-acting-antiretroviral-therapy-suppresses-hiv-among-people-with-unstable-housing-mental-illnesses-substance-use